BiotechTube

ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalation

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Perennial Allergic Rhinitis

Conditions

Perennial Allergic Rhinitis

Trial Timeline

Feb 1, 2011 → Apr 1, 2011

NCT ID
NCT01287364

About ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalation

ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalation is a phase 3 stage product being developed by Sumitomo Pharma for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01287364. Target conditions include Perennial Allergic Rhinitis.

What happened to similar drugs?

7 of 20 similar drugs in Perennial Allergic Rhinitis were approved

Approved (7) Terminated (1) Active (13)
🔄LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
✅ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
🔄ciclesonide + mometasoneSumitomo PharmaPhase 3
🔄ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
🔄Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
🔄Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
🔄ciclesonide HFA 160 μgSumitomo PharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01287364Phase 3Completed

Competing Products

20 competing products in Perennial Allergic Rhinitis

See all competitors
ProductCompanyStageHype Score
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
43
ciclesonide + mometasoneSumitomo PharmaPhase 3
40
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
ciclesonide HFA 160 μgSumitomo PharmaPhase 3
40
Budesonide + PlaceboAstraZenecaApproved
43
Ciclesonide + PlaceboAstraZenecaPhase 3
40
CiclesonideAstraZenecaPhase 3
40
CiclesonideAstraZenecaPhase 3
40
Ciclesonide nasal + PlaceboAstraZenecaPhase 3
40
Ciclesonide + PlaceboAstraZenecaPhase 3
40
Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
43
CiclesonideAstraZenecaPhase 3
40
MK-8237 tablets + Placebo tablets + Rescue Medication: Self-Injectable Epinephrine + Rescue Medication: Loratadine tablets + Rescue Medication: Olopatadine ophthalmic drops + Rescue Medication: Mometasone furoate nasal sprayMerckPhase 3
40
Placebo + Montelukast + Fluticasone propionateMerckApproved
35
montelukast + placeboMerckApproved
43
MK-8237 6 DU + MK-8237 12 DU + PlaceboMerckPhase 1
29
loratadine + loratadine + loratadineMerckApproved
43